News | May 11, 2023
FSD Pharma completes dosing of first cohort in Phase I clinical trial of Lucid-MS
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Subscribe To Our Newsletter & Stay Updated
